IP Library Granted Patent US 8,153,640
Granted Patent B2
US 8,153,640 · App. 11/718,181 · Granted Apr 10, 2012

HIV inhibiting bicyclic pyrimdine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,640
App. No.
11/718,181
Granted
Apr 10, 2012
Kind
B2
Abstract

HIV replication inhibitors of formula N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a 1 =a 2 -a 3 =a 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b 1 =b 2 -b 3 =b 4 - is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0, 1, 2, 3 and in certain cases also 4; R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; optionally substituted C 1-6 alkyl; C 1-6 alkyloxycarbonyl; R 2 is OH; halo; optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; substituted amino; polyhalomethyl; polyhalomethylthio; —S(═O) p R 6 ; C(═NH)R 6 ; R 2a is CN; amino; substituted amino; optionally substituted C 1-6 alkyl; halo; optionally substituted C 1-6 alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R 16 ; optionally substituted C 1-6 alkyloxyC 1-6 alkyl; substituted C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 or —X—R 7 ; R 3 is CN; amino; C 1-6 alkyl; halo; optionally substituted C 1-6 alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R 16 ; substituted C 1-6 alkyl; optionally substituted C 1-6 alkyloxyC 1-6 alkyl; substituted C 2-6 alkenyl or C 2-6 alkynyl; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 ; —X—R 7 ; R 4 is halo; OH; optionally substituted C 1-6 alkyl, C 2-6 alkenyl or C 2-6 alkynyl; C 3-7 cycloalkyl; C 1-6 alkyloxy; CN; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino or R 7 ; -A-B— is —CR 5 ═N—, —N═N—, —CH 2 —CH 2 —, —CS—NH—, —CO—NH—, —CH═CH—; pharmaceutical compositions comprising these; methods for the preparation of these compounds and compositions; the use of these compounds for the prevention or the treatment of HIV infection.

Claims (117)

1. A compound of formula

a N-oxide; a pharmaceutically acceptable addition salt; a quaternary amine; or a stereochemically isomeric form thereof, wherein

-a 1 =a 2 -a 3 =a 4 - represents a bivalent radical of formula

—CH═CH—CH═CH—  (a-1);

—N═CH—CH═CH—  (a-2);

—N═CH—N═CH—  (a-3);

—N═CH—CH═N—  (a-4); or

—N═N—CH═CH—  (a-5);

-b 1 =b 2 -b 3 =b 4 - represents a bivalent radical of formula

—CH═CH—CH═CH—  (b-1);

—N═CH—CH═CH—  (b-2);

—N═CH—N═CH—  (b-3);

—N═CH—CH═N—  (b-4); or

—N═N—CH═CH—  (b-5);

n is 0, 1, 2, 3 and in case -a 1 =a 2 -a 3 =a 4 - is (a-1), then n may also be 4;

m is 0, 1, 2, 3 and in case -b 1 =b 2 -b 3 =b 4 - is (b-1), then m may also be 4;

-A-B— represents a bivalent radical of formula

—CR 5 ═N—  (c-1);

R 1 is hydrogen; aryl; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; C 1-6 alkyloxycarbonyl; or C 1-6 alkyl substituted with formyl, C 1-6 alkylcarbonyl, or with C 1-6 alkyloxycarbonyl;

each R 2 independently is hydroxy; halo; C 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 3-7 cycloalkyl; C 2-6 alkenyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 1-6 alkyloxycarbonyl; carboxyl; cyano; nitro; amino; mono- and di(C 1-6 alkyl)amino; polyhalomethyl; polyhalomethylthio; —S(═O) p R 6 ; —NH—S(═O) p R 6 ; —C(═O)R 6 ; —NHC(═O)H; —C(═O)NHNH 2 ; NHC(═O)R 6 ; or C(═NH)R 6 ;

R 2a is cyano; aminocarbonyl; amino; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy is substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 or —X—R 7 ;

R 3 is cyano; aminocarbonyl; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy may optionally be substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 or —X—R 7 ;

X is —NR 1 —, —O—, —C(═O)—, —S—, or —S(═O) p —;

each R 4 independently is halo; hydroxy; C 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkenyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one, two or three substituents each independently selected from halo, cyano and —C(═O)R 6 ; C 3-7 cycloalkyl; C 1-6 alkyloxy; cyano; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; aminocarbonyl; mono- or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkyloxycarbonyl; C 1-6 alkylcarbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino or R 7 ;

Q is hydrogen, C 1-6 alkyl, halo, polyhaloC 1-6 alkyl, or —NR 9 R 10 ;

R 5 is hydrogen, C 1-6 alkyl, aryl, pyridyl, thienyl, furanyl, amino, mono- or di(C 1-4 alkyl)amino;

R 6 is C 1-4 alkyl, amino, mono- or di(C 1-4 alkyl)amino or polyhaloC 1-4 alkyl;

R 7 is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C 1-6 alkyl, hydroxy C 1-6 alkyl, aminoC 1-6 alkyl, mono and di(C 1-6 alkyl)amino C 1-6 alkyl, formyl, C 1-6 alkylcarbonyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, C 1-6 alkylthio, cyano, nitro, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, aminocarbonyl, —CH(═N—O—R 8 ), R 7a , —X—R 7a and R 7a —C 1-4 alkyl;

R 7a is a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic carbocycle or a monocyclic, bicyclic or tricyclic saturated, partially saturated or aromatic heterocycle, wherein each of said carbocyclic or heterocyclic ring systems may optionally be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, mono or di(C 1-6 alkyl)amino C 1-6 alkyl, formyl, C 1-6 alkylcarbonyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1-6 alkyloxycarbonyl, C 1-6 alkylthio, cyano, nitro, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, aminocarbonyl, and —CH(═N—O—R 8 );

R 8 is hydrogen, C 1-4 alkyl, aryl or arylC 1-4 alkyl;

R 9 and R 10 each independently are hydrogen; hydroxy; C 1-6 alkyl; C 1-6 alkyloxy; C 1-6 alkylcarbonyl; C 1-6 alkyloxycarbonyl; amino; mono- or di(C 1-6 alkyl)amino; mono- or di(C 1-6 alkyl)aminocarbonyl; —CH(═NR 11 ) or R 7 , wherein each of the aforementioned C 1-6 alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, carboxyl, C 1-6 alkyloxycarbonyl, cyano, amino, imino, mono- and di(C 1-4 alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O) p R 6 , —NH—S(═O) p R 6 , —C(═O)R 6 , —NHC(═O)H, —C(═O)NHNH 2 , —NHC(═O)R 6 , —C(═NH)R 6 , R 7 ; or

R 9 and R 10 may be taken together to form a bivalent or trivalent radical of formula

—CH 2 —CH 2 —CH 2 —CH 2 —  (d-1);

—CH 2 —CH 2 —CH 2 —CH 2 —CH 2 —  (d-2);

—CH 2 —CH 2 —O—CH 2 —CH 2 —  (d-3);

—CH 2 —CH 2 —S—CH 2 —CH 2 —  (d-4);

—CH 2 —CH 2 —NR 12 —CH 2 —CH 2 —  (d-5);

—CH 2 —CH═CH—CH 2 —  (d-6); or

═CH—CH═CH—CH═CH—  (d-7);

R 11 is cyano; C 1-4 alkyl optionally substituted with C 1-4 alkyloxy, cyano, amino, mono- or di(C 1-4 alkyl)amino or aminocarbonyl; C 1-4 alkylcarbonyl; C 1-4 alkyloxycarbonyl; aminocarbonyl; mono- or di(C 1-4 alkyl)aminocarbonyl;

R 12 is hydrogen or C 1-4 alkyl;

R 13 and R 14 each independently are C 1-6 alkyl optionally substituted with cyano or aminocarbonyl,

C 2-6 alkenyl optionally substituted with cyano or aminocarbonyl, or

C 2-6 alkynyl optionally substituted with cyano or aminocarbonyl;

R 15 is C 1-6 alkyl substituted with cyano or aminocarbonyl;

R 16 is C 1-6 alkyl optionally substituted with cyano or aminocarbonyl, or R 7 ;

each p is 1 or 2;

each aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, mercapto, C 1-6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, mono or di(C 1-6 alkyl)aminoC 1-6 alkyl, C 1-6 alkylcarbonyl, C 3-7 cycloalkyl, C 1-6 alkyloxy, C 1- 6alkyloxycarbonyl, C 1-6 alkylthio, cyano, nitro, polyhaloC 1-6 alkyl, polyhaloC 1-6 alkyloxy, aminocarbonyl, a radical Het and —X-Het; and

Het is pyridyl, thienyl, furanyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, thiadiazolyl, oxadiazolyl quinolinyl, benzothienyl, or benzofuranyl; which each may optionally be substituted with one or two C 1-4 alkyl radicals.

2. A compound according to claim 1 , wherein

-a 1 =a 2 -a 3 =a 4 - represents a bivalent radical of formula —CH═CH—CH═CH— (a-1);

-b 1 =b 2 -b 3 =b 4 - represents a bivalent radical of formula —CH═CH—CH═CH— (b-1);

n is 0, 1 or 2;

m is 0, 1 or 2; and

R 1 is hydrogen; formyl; C 1-6 alkylcarbonyl; C 1-6 alkyl; or C 1-6 alkyloxycarbonyl.

3. A compound according to claim 1 , wherein the compound has the formula

wherein R 1 , R 2 , R 2a , R 3 , R 4 , -A-B—, m, n and Q are as defined in claim 1 .

4. A compound according to claim 1 , wherein the compound has the formula

wherein R 1 , R 2a , R 3 , R 4 , -A-B— and Q are as defined in claim 1 .

5. A compound according to claim 1 , wherein

R 2 is hydroxy; halo; C 1-6 alkyl optionally substituted with one substituent selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkenyl optionally substituted with one substituent selected from halo, cyano or —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one substituent selected from halo, cyano or —C(═O)R 6 ; C 1-6 alkyloxycarbonyl; carboxyl; cyano; nitro; amino; mono- and di(C 1-6 alkyl)amino; or trifluoromethyl;

R 2a is cyano; aminocarbonyl; amino; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy is substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one substituent selected from halo, cyano, —C(═O)—NR 9 R 10 , and —C(═O)—C 1-6 alkyl; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, —C(═O)—NR 9 R 10 , and —C(═O)—C 1-6 alkyl; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one substituent selected from halo, cyano, —C(═O)—NR 9 R 10 , and —C(═O)—C 1-6 alkyl; C 2-6 alkenyl substituted with one substituent selected from halo, cyano, —C(═O)—NR 9 R 10 , and —C(═O)—C 1-6 alkyl; or C 2-6 alkynyl substituted with one substituent selected from halo, cyano, —C(═O)—NR 9 R 10 , and —C(═O)—C 1-6 alkyl;

R 3 is cyano; aminocarbonyl; amino; C 1-6 alkyl; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy may optionally be substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one substituent selected from halo, cyano, and —C(═O)—NR 9 R 10 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, and —C(═O)—NR 9 R 10 ; C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one substituent selected from halo, cyano, and —C(═O)—NR 9 R 10 ; C 2-6 alkenyl substituted with one substituent selected from halo, cyano, and —C(═O)—NR 9 R 10 ; or C 2-6 alkynyl substituted with one substituent selected from halo, cyano, and —C(═O)—NR 9 R 10 ; and

R 4 is halo; hydroxy; C 1-6 alkyl optionally substituted with one substituent selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkenyl optionally substituted with one substituent selected from halo, cyano and —C(═O)R 6 ; C 2-6 alkynyl optionally substituted with one substituent selected from halo, cyano and —C(═O)R 6 ; C 3-7 cycloalkyl; C 1-6 alkyloxy; cyano; nitro; polyhaloC 1-6 alkyl; polyhaloC 1-6 alkyloxy; aminocarbonyl; mono- or di(C 1-4 alkyl)amino-carbonyl; C 1-6 alkyloxycarbonyl; C 1-6 alkylcarbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino or R 7 .

6. A compound according to claim 1 , wherein R 1 is hydrogen.

7. A compound according to claim 1 , wherein

R 2 is halo, cyano, aminocarbonyl, C 1-6 alkyl, C 1-6 alkyl substituted with cyano or C 2-6 alkenyl substituted with cyano;

R 2a is halo, cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or aminocarbonyl, or C 2-6 alkenyl substituted with cyano or aminocarbonyl;

R 3 is halo, cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or aminocarbonyl, or C 2-6 alkenyl substituted with cyano or aminocarbonyl;

R 4 is halo; hydroxy; C 1-6 alkyl optionally substituted with cyano; C 2-6 alkenyl optionally substituted with cyano; C 2-6 alkynyl optionally substituted with cyano; C 1-6 alkyloxy; cyano; nitro; trifluoromethyl; aminocarbonyl; mono- or di(C 1-4 alkyl)aminocarbonyl; C 1-6 alkyloxycarbonyl; C 1-6 alkylcarbonyl; formyl; amino; mono- or di(C 1-4 alkyl)amino; and

Q is hydrogen, amino, mono- or di-C 1-4 alkylamino.

8. A compound according to claim 1 wherein

n is 0;

m is 2;

R 2 is halo, cyano, aminocarbonyl, C 1-4 alkyl substituted with cyano or C 2-4 alkenyl substituted with cyano;

R 2a is cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or C 2-6 alkenyl substituted with cyano;

R 3 is cyano, C 1-4 alkyl substituted with cyano or C 2-4 alkenyl substituted with cyano;

R 4 is halo, hydroxy, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkyloxy, cyano, nitro, amino; and

Q is hydrogen.

9. A compound according to claim 1 wherein

R 2 is cyano, aminocarbonyl;

R 2a is cyano, aminocarbonyl, C 1-4 alkyl substituted with cyano or C 2-4 alkenyl substituted with cyano;

R 3 is C 1-4 alkyl substituted with cyano or C 2-4 alkenyl substituted with cyano;

R 4 is halo, C 1-4 alkyl, C 1-4 alkyloxy; and

Q is hydrogen.

10. A compound according to claim 1 wherein

R 2a is cyano; aminocarbonyl; amino; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy is substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl or R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

—C(═N—O—R 8 )—C 1-4 alkyl; R 7 and —X—R 7 ; and

R 3 is cyano; aminocarbonyl; amino; halo; C 1-6 alkyloxy wherein the C 1-6 alkyl moiety of the C 1-6 alkyloxy is substituted with cyano; NHR 13 ; NR 13 R 14 ; —C(═O)—NHR 13 ; —C(═O)—NR 13 R 14 ; —C(═O)—R 15 ; —CH═N—NH—C(═O)—R 16 ; C 1-6 alkyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ; C 1-6 alkyl substituted with hydroxy and a second substituent selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 1-6 alkyloxyC 1-6 alkyl optionally substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 2-6 alkenyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl and R 7 ;

C 2-6 alkynyl substituted with one, two or three substituents each independently selected from halo, cyano, NR 9 R 10 , —C(═O)—NR 9 R 10 , —C(═O)—C 1-6 alkyl or R 7 ; —C(═N—O—R 8 )—C 1-4 alkyl; R 7 and —X—R 7 .

11. A compound according to claim 1 wherein

R 2a is halo, cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or aminocarbonyl, C 2-6 alkenyl optionally substituted with cyano or aminocarbonyl; and

R 3 is halo, cyano, aminocarbonyl, C 1-6 alkyl optionally substituted with cyano or aminocarbonyl, C 2-6 alkenyl optionally substituted with cyano or aminocarbonyl.

12. A compound according to claim 1 wherein

R 2a is halo, cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or aminocarbonyl, or C 2-6 alkenyl substituted with cyano or aminocarbonyl; and

R 3 is halo, cyano, aminocarbonyl, C 1-6 alkyl substituted with cyano or aminocarbonyl, or C 2-6 alkenyl substituted with cyano or aminocarbonyl.

13. A compound according to claim 1 , wherein

R 3 is C 2-6 alkyl substituted with cyano, or C 2-6 alkenyl substituted with cyano.

14. A compound according to claim 12 , wherein

R 2a is cyano or aminocarbonyl.

15. A compound according to claim 14 , wherein R 2a is cyano.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredient a therapeutically effective amount of a compound as claimed in claim 1 .

17. A process for preparing a pharmaceutical composition, said process comprising mixing as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 with a pharmaceutically acceptable carrier.

18. A process for preparing a compound as claimed in claim 1 , said process comprising:

(a) reacting an intermediate of formula (II-a) or (II-b) with an intermediate of formula (III-a) or (III-b), in a suitable solvent:

wherein each W independently represents a suitable leaving group;

(b) reacting the bicyclic derivative (IV) with an intermediate (V), in a suitable solvent:

wherein W represents an appropriate leaving group;

(c) preparing compounds of formula (I-c) which are compounds of formula (I) wherein -A-B— is —CR 5 ═N— by reacting an aminopyrimidine (VIII) with an orthoformate R 5 C(OEt) 3 or with an aldehyde R 5 CH═O in the presence of a mild oxidant:

(d) preparing compounds of formula (I-c-1) which are compounds of formula (I) wherein -A-B— is —CR 5 ═N— wherein R 5 is amino, by reacting an aminopyrimidine (VIII) with a cyanogen halide, in a suitable solvent:

(e) mono- or bis-alkylating compounds of formula (I-c-1) to the corresponding compounds wherein R 5 is mono- or di(C 1-4 alkyl)amino using a reagent C 1-4 alkyl-W as alkylating agent;

(f) and if desired, preparing salt-forms by treating the free base or acid form of a compound of formula (I) with a suitable acid or base; or vice versa, preparing free base or acid forms by treating the salt forms of a compound of formula (I) with a suitable base or acid.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNMENT DOCUMENT ATTACHMENT PREVIOUSLY RECORDED ON REEL 019522 FRAME 0962. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 17, 2017
From: GUILLEMONT, JERÔME EMILE GEORGES; PAUGAM, MIKAËL; DELEST, BRUNO FRANCOIS MARIE; HEERES, JAN; LEWI, PAULUS JOANNES; ARTS (ESTATE EXECUTOR FOR PAUL ADRIAAN JAN JANSSEN), FRANK XAVIER JOZEF HERWIG
To: JANSSEN-CILAG
Reel/Frame 042491/0048 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: JANSSEN R & D IRELAND
To: JANSSEN SCIENCES IRELAND UC
Reel/Frame 035496/0382 →
CHANGE OF NAME Recorded Apr 15, 2015
From: TIBOTEC PHARMACEUTICALS
To: JANSSEN R&D IRELAND
Reel/Frame 035439/0981 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2007
From: GUILLEMONT, JEROME EMILE GEORGES; PAUGAM, MIKAEL; DELEST, BRUNO FRANCOIS MARIE; HEERES, JAN; LEWI, PAULUS JOANNES; ARTS, FRANK XAVIER JOZEF HERWIG
To: JANSSEN-CILAG
Reel/Frame 019522/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2007
From: JANSSEN PHARMACEUTICA N.V.
To: TIBOTEC PHARMACEUTICALS LTD.
Reel/Frame 019523/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2007
From: JANSSEN-CILAG
To: TIBOTEC PHARMACEUTICALS LTD.
Reel/Frame 019523/0729 →